A panel of GE Healthcare experts discusses the future of healthcare innovation —
how it relates to the concepts of early health and personalized medicine to molecular
technology and “cyber experience” for physicians
Joe Ficalora, SBTI’s President of Global Services, shares
how Lean Six Sigma tools can transform a pharmaceutical
company’s business on multiple fronts and improve the
organization from top line to bottom line
Dr. Miodrag Micic, Vice President of Research and Development, MP Biomedicals, talks about his
development of the FastPrep-24 line of products for the molecular biology sample preparation of difficult - toprepare
samples, and shares his views on market trends in drug discovery tools in difficult economic times.
Dave Rock, President and Managing Director of Paragon International, Inc. speaks about how a
successful meeting can lead to a successful product, and why Paragon doesn’t only do meeting “planning”
Rick Connell, Vice President and
Worldwide Head of External Research
Solutions, Pfizer Global Research & Development,
moderates an expert panel discussion around the emerging
realm of risk share in drug discovery, and speaks with
Mark Ashton, Executive Vice President of Business
Development, Evotec, Bill Farley, Vice President of
Business Development, ChemDiv, and Sri Mosur,
CEO and President, Jubilant Discovery Services.
Frost & Sullivan’s
DR. Sudeep Basu discusses the role of biomarkers.
Rider University’s Tan Miller
discusses frameworks
Shire’s Peter Dibiaso
discusses the improving
public perception of the
pharma industry
Frost & Sullivan’s DR. Sudeep Basu
discusses HPC and grid computing
Lisa Keilty , CMP, Manager, Meeting Development Team, Pfizer Inc., discusses the current responsibilities and challenges of pharmaceutical meeting planners.
Greater Philadelphia Region Healthcare Nonprofits to Receive Up to $400,000 in Funding - Application Deadline July 15, 2009 The GlaxoSmithKline IMPACT Awards target community-based nonprofits that provide access to healthcare for the underserved.
Repairing cartilage is one of the Holy Grails of orthopedics. ISTO Technologies of St. Louis says it has a cell-based therapy utilizing juvenile chondrocytes which may repair cells in a damaged disc. Now the FDA has given them the chance to prove it.
IVI Destinations highlights a few reasons why Costa Rica
is a prime location for industry meetings and events.
Some are touting risk-share plans as the absolute future for drug
discovery; others are worried that the investment will not be worth
the trouble. Rick Connell, Vice President and Worldwide Head
of External Research Solutions, Pfizer Global Research &
Development, discusses the emerging field from a client’s point
of view and delves into the origins, benefits and risks surrounding
integrated sourcing models.
At the annual Drug Information Association's conference, "Marketing Pharmaceuticals in a Time of Change,” drug promotion and direct-to-consumer advertising were hot topics.
Read on for insight from the FDA on how to preempt future violations.